Ken Griffin Biotechnology

Citadel Advisors LLC

  • $509 Billion
  • Q1 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
NAUT
Nautilus Biotechnology, Inc.
CALL
$24,000
28.5K
Q1 2025
Reduced 53.26%
OLMA
Olema Pharmaceuticals, Inc.
CALL
$23,000
6.3K
Q1 2025
Added 11.25%
ORMP
Oramed Pharmaceuticals Inc.
CALL
$23,000
11.2K
Q1 2025
Reduced 99.95%
ALXO
Alx Oncology Holdings Inc
PUT
$22,000
36.9K
Q1 2025
Reduced 94.05%
ATOS
Atossa Therapeutics, Inc.
CALL
$22,000
33.8K
Q4 2024
Added 164.25%
RVPH
Reviva Pharmaceuticals Holdings, Inc.
PUT
$22,000
23.7K
Q1 2025
New holding
FATE
Fate Therapeutics Inc
CALL
$21,000
26.7K
Q1 2025
Reduced 2.12%
XNCR
Xencor Inc
PUT
$20,000
1.9K
Q1 2025
Reduced 51.07%
TRDA
Entrada Therapeutics, Inc.
PUT
$20,000
2.3K
Q1 2025
Reduced 76.72%
PYXS
Pyxis Oncology, Inc.
CALL
$19,000
19.5K
Q3 2024
New holding
STOK
Stoke Therapeutics, Inc.
CALL
$19,000
2.9K
Q1 2025
Added 16.18%
KMPH
Kempharm, Inc
PUT
$19,000
3.9K
Q1 2025
Added 9897.27%
ZNTL
Zentalis Pharmaceuticals, Inc.
PUT
$18,000
11.6K
Q1 2025
Reduced 97.79%
VTYX
Ventyx Biosciences, Inc.
CALL
$18,000
16.2K
Q1 2025
Reduced 68.91%
CVM
Cel Sci Corp
PUT
$18,000
80K
Q3 2024
Reduced 25.37%
CSBR
Champions Oncology, Inc.
PUT
$18,000
2.1K
Q1 2025
Added 110.73%
NKTX
Nkarta, Inc.
PUT
$18,000
10.3K
Q1 2025
Reduced 1.57%
PRLD
Prelude Therapeutics Inc
CALL
$18,000
23.9K
Q1 2025
Reduced 99.67%
DYAI
Dyadic International Inc
CALL
$17,000
13K
Q3 2024
Added 35.37%
PMCB
Pharma Cyte Biotech, Inc.
CALL
$17,000
13.7K
Q1 2024
Reduced 70.09%
RGLS
Regulus Therapeutics Inc.
CALL
$17,000
9.9K
Q1 2025
Reduced 4.68%
RZLT
Rezolute, Inc.
CALL
$17,000
5.9K
Q1 2025
Reduced 65.71%
CVM
Cel Sci Corp
CALL
$16,000
73.8K
Q3 2024
Reduced 25.37%
ELEV
Elevation Oncology, Inc.
CALL
$16,000
65K
Q4 2024
New holding
GANX
Gain Therapeutics, Inc.
CALL
$16,000
8.4K
Q1 2025
Added 63.79%
GANX
Gain Therapeutics, Inc.
PUT
$16,000
8.7K
Q1 2025
Added 63.79%
IMAB
I Mab
CALL
$16,000
20K
Q4 2024
Reduced 99.05%
OCGN
Ocugen, Inc.
CALL
$16,000
22.8K
Q1 2025
Added 73.17%
CRBU
Caribou Biosciences, Inc.
CALL
$15,000
17.1K
Q3 2024
Added 3.15%
CDXS
Codexis, Inc.
PUT
$15,000
5.9K
Q1 2025
Added 192.81%
DSGN
Design Therapeutics, Inc.
CALL
$15,000
4K
Q1 2025
Added 0.49%
ORIC
Oric Pharmaceuticals, Inc.
PUT
$15,000
2.7K
Q1 2025
Added 1305.28%
TARA
Protara Therapeutics, Inc.
PUT
$15,000
3.7K
Q1 2025
Reduced 59.85%
ALXO
Alx Oncology Holdings Inc
CALL
$14,000
23.9K
Q1 2025
Reduced 94.05%
ALLK
Allakos Inc.
CALL
$13,000
56.6K
Q4 2024
Reduced 7.47%
CELC
Celcuity Inc.
CALL
$13,000
1.3K
Q1 2025
Added 13.45%
OCUP
Ocuphire Pharma, Inc.
CALL
$13,000
13.7K
Q1 2025
Reduced 61.38%
HOWL
Werewolf Therapeutics, Inc.
PUT
$13,000
13.6K
Q3 2024
Reduced 82.01%
VXRT
Vaxart, Inc.
PUT
$13,000
34K
Q4 2024
New holding
ZNTL
Zentalis Pharmaceuticals, Inc.
CALL
$12,000
7.9K
Q1 2025
Reduced 97.79%
ADAP
Adaptimmune Therapeutics PLC
CALL
$12,000
61.9K
Q4 2024
New holding
ACET
Adicet Bio, Inc.
PUT
$12,000
16.5K
Q1 2025
Added 6067.69%
GLYC
Glycomimetics Inc
CALL
$12,000
59K
Q1 2024
Added 25.72%
INZY
Inozyme Pharma, Inc.
CALL
$12,000
13.8K
Q1 2025
Reduced 70.82%
PGEN
Precigen, Inc.
PUT
$12,000
8.6K
Q3 2024
Reduced 8.76%
TBPH
Theravance Biopharma, Inc.
PUT
$12,000
1.4K
Q1 2025
Added 39.44%
AVTE
Aerovate Therapeutics, Inc.
PUT
$11,000
4.6K
Q1 2025
Added 466.67%
DSGN
Design Therapeutics, Inc.
PUT
$11,000
3.1K
Q1 2025
Added 0.49%
SVRA
Savara Inc
PUT
$11,000
4.1K
Q1 2025
Added 190.67%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email